MD Anderson and Erasca form R&D collaboration in RAS/MAPK-driven cancers

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

The University of Texas MD Anderson Cancer Center announced a $10 million gift from Peggy and Carl Sewell to establish the Center for Cellular Language Intelligence, a research center created to understand the behavior of cancer cells at a high resolution, potentially enabling earlier cancer detection, smarter prevention, and more precise, personalized treatments.

May 01, 2026

Vol.52 No.17

In Brief

UT Austin announces first tech-native academic medical center in the U.S.

The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.

April 24, 2026

Vol.52 No.16

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.

March 27, 2026

Vol.52 No.12

In Brief

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon were appointed members of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

March 06, 2026

Vol.52 No.09

MD Anderson and Erasca form R&D collaboration in RAS/MAPK-driven cancers

YOU MAY BE INTERESTED IN

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

UT Austin announces first tech-native academic medical center in the U.S.

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson and Erasca form R&D collaboration in RAS/MAPK-driven cancers

YOU MAY BE INTERESTED IN

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

UT Austin announces first tech-native academic medical center in the U.S.

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”